Disturbing the Redox Balance Using Buthionine Sulfoximine Radiosensitized Somatostatin Receptor-2 Expressing Pre-Clinical Models to Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATE

Disturbing the Redox Balance Using Buthionine Sulfoximine Radiosensitized Somatostatin Receptor-2 Expressing Pre-Clinical Models to Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATE

Peptide receptor radionuclide therapy with <sup>177</sup>Lu-DOTATATE improves the outcome of patients with somatostatin receptor (SSTR)-expressing neuroendocrine tumours. Nevertheless, stable disease has been the main response pattern observed, with some rare complete responses. Lu-177 e...

Full description

Bibliographic Details
Main Authors: Wendy Delbart, Gwennaëlle Marin, Basile Stamatopoulos, Roland de Wind, Nicolas Sirtaine, Pieter Demetter, Marie Vercruyssen, Erwin Woff, Ioannis Karfis, Ghanem E. Ghanem, Patrick Flamen, Zéna Wimana
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Cancers
Subjects:
peptide receptor radionuclide therapy
<sup>177</sup>Lu-DOTATATE
radiosensitization
antioxidant defenses
BSO
glutathione
Online Access:https://www.mdpi.com/2072-6694/15/8/2332

Internet

https://www.mdpi.com/2072-6694/15/8/2332

Similar Items